EGF receptor (EGFR) inhibitor
Jump to navigation
Jump to search
Adverse effects
- rash (acneiform eruption)
- topical clindamycin 2% plus hydrocortisone 1% lotion BID until resolution of the rash, plus minocycline 100 mg PO BID for a minimum of 4 weeks & continuing until resolution of the rash (NGC [CancerControl Alberta])[1]
- paronychia[1]
- interstitial lung disease[2] Mechanism:
- inhibits EGF receptor
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of EGF receptor inhibitors
More general terms
More specific terms
- afatinib (Gilotrif)
- cetuximab (Erbitux)
- erlotinib (Tarceva)
- gefitinib (Iressa)
- necitumumab (Portrazza)
- osimertinib (Tagrisso)
- panitumumab (Vectibix)
References
- ↑ 1.0 1.1 1.2 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 2.0 2.1 Rosell R, Carcereny E, Gervais R et al Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22285168 Clinical Trial.